Which statement should a nurse include when educating a client about neostigmine for myasthenia gravis?

Which statement should a nurse include when educating a client about neostigmine for myasthenia gravis?

• A. "It will decrease your muscle weakness."
• B. "It increases muscle strength."
• C. "It will help you gain more energy."
• D. "It has no adverse effects on muscle activity."

Answer: (B)

When educating a client about neostigmine for myasthenia gravis, stating that it "increases muscle strength" is correct and provides a clear understanding of the medication's primary function. Neostigmine is an acetylcholinesterase inhibitor that works by preventing the breakdown of acetylcholine at the neuromuscular junction. This leads to an increased availability of acetylcholine, which enhances communication between nerve endings and muscle fibers. As a result, this facilitates improved muscle contraction and strength, which is especially beneficial for individuals with myasthenia gravis, a condition characterized by muscle weakness due to impaired transmission of nerve impulses. The other statements do not accurately depict the action of neostigmine. For example, saying it "will decrease your muscle weakness" may imply a reduction in weakness rather than an enhancement of strength. While neostigmine does indeed help address muscle weakness, the more precise description is that it increases strength. The statement about gaining more energy suggests a systemic effect that is not directly related to the specific action of the medication on muscle activity. Lastly, the claim of having "no adverse effects on muscle activity" is misleading. While neostigmine is beneficial in increasing muscle strength, it can

When educating a client about neostigmine for myasthenia gravis, stating that it "increases muscle strength" is correct and provides a clear understanding of the medication's primary function. Neostigmine is an acetylcholinesterase inhibitor that works by preventing the breakdown of acetylcholine at the neuromuscular junction. This leads to an increased availability of acetylcholine, which enhances communication between nerve endings and muscle fibers. As a result, this facilitates improved muscle contraction and strength, which is especially beneficial for individuals with myasthenia gravis, a condition characterized by muscle weakness due to impaired transmission of nerve impulses.

The other statements do not accurately depict the action of neostigmine. For example, saying it "will decrease your muscle weakness" may imply a reduction in weakness rather than an enhancement of strength. While neostigmine does indeed help address muscle weakness, the more precise description is that it increases strength. The statement about gaining more energy suggests a systemic effect that is not directly related to the specific action of the medication on muscle activity. Lastly, the claim of having "no adverse effects on muscle activity" is misleading. While neostigmine is beneficial in increasing muscle strength, it can